Nuvation Bio taking multimechanism approach with $275M series A

With a management team stocked with ex-Medivation execs, Nuvation aims to develop a broad oncology pipeline

Nuvation’s lead investor believes the experience of its management team and its multitarget approach to oncology will be key differentiators as the start-up maps out a plan to deploy its $275 million series A round. The company already has

Read the full 394 word article

User Sign In